English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Diabetes is characterized by chronic hyperglycemia and disturbances of carbohydrate, lipid and protein metabolism. This study is an attempt to show an improvement in lipid profile (TC, TG, LDL and HDL) in patients of type 2 diabetes mellitus who were previously on metformin monotherapy with uncontrolled diabetes. Material and method: A total of 30 patients were enrolled who were on metformin monotherapy and with uncontrolled diabetes. Patients were given metformin 500 mg twice a day and saxagliptin 2.5 mg once a day. Patients were followed up at 1st, 3rd and 6th month and lipid profile (TC, TG, LDL and HDL) estimation was done during the follow up period. Results: The mean age ± SD in male and female patients was 61.42 yrs ± 6.99 and 55.93 yrs ± 5.74 respectively. The mean change in value from baseline at 24 weeks was TC = 9.66%, TG = 9.40%, LDL = 14.87%, HDL = 5.63%. A highly significant difference has been seen at 0 v/s 1, 0 v/s 3 and 0 v/s 6 months in TC, TG, LDL and HDL values. Conclusion: Saxagliptin has shown an improvement in lipid profile (TC, TG, LDL, HDL) during 6 months of treatment in patients of type 2 DM.  Keywords: Saxagliptin, Uncontrolled type 2DM, Metformin, Lipid profile.

ip international journal of comprehensive and advanced pharmacology/ip international journal of comprehensive and advanced pharmacology

Improvement in lipid profile of the patients with saxagliptin as add on therapy to metformin in patients of type 2 DM who were previously on metformin alone with uncontrolled diabetes